Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 天前评分90
正文 · 原文
#ESMO26 🧬 G-HOPE-001 | Phase III
👥 460 pts | CLDN18.2+ G/GEJA, ≥3L
💊 Arcotatug tavatecan (ADC) vs TPC
📈 PFS: 7.1 vs 3.1 mo (HR 0.45; updated)
⏳ OS: 10.2 vs 6.9 mo (HR 0.57; p<0.0001)
🎯 ORR: 37.4% vs 7.7%
🚀 Significant PFS & OS benefit!
@OncoAlert
4060 浏览 · 17 赞 · 12 转发 · 0 回复
会议摘要
LBA77按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com